BofA Securities Downgrades ResMed (RMD) to Underperform on Valuation

BofA Securities analyst Lyanne Harrison downgraded ResMed (NYSE: RMD) from Neutral to Underperform with a price target of $221.00 (from $216.00) on valuation after an "over-reaction" to the Phillips recall.

The analyst commented, "We downgrade ResMed (RMD)to Underperform from Neutral. Whilst we like the company and are positive on the long term outlook, we believe that the market has over-reacted (+8%) to competitor’s product recall. The stock is trading at an all-time share price high and well above 1SD historical P/E (see Exhibit 1). We lift our PO to $221 per share (from $216/share) to reflect potential revenue upside (FY22 +$25m) and market share gains (BofAe FY22 RMD +3%/ Philips (PHIA) -3%) but note that this is not without challenges."

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $236.46 yesterday.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
• Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'